ArticleBMC ophthalmology2025
The clinical outcomes of lamellar keratomileusis in patients with human immunodeficiency virus positivity.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven improved survival, HIV + patients are now more likely to pursue common elective procedures, such as refractive surgery. We sought to assess the safety, efficacy, predictability, and stability of lamellar keratomileusis in patients with HIV.
methodsA study was conducted with 14 patients (28 eyes) HIV-positive patients at Ineye Hospital of Chengdu University of Traditional Chinese Medicine, who underwent lamellar keratomileusis. They were observed for at least one year. 8 patients (16 eyes) had femtosecond laser-assisted in situ keratomileusis (FS-LASIK) and 6 patients (12 eyes) received small incision lenticule extraction (SMILE). Measurements taken before and after surgery included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refraction, spherical equivalent (SE), intraocular pressure, and any complications.
resultsAt one year postoperatively, all groups showed significant UDVA improvement (P < 0.001): overall from 1.36 ± 0.18 LogMAR to -0.07 ± 0.07 LogMAR, SMILE from 1.37 ± 0.18 LogMAR to -0.09 ± 0.07 LogMAR, and FS-LASIK from 1.35 ± 0.19 LogMAR to -0.11 ± 0.06 LogMAR, with all patients achieving a UDVA of 20/20 or better. Only 2 eyes (7.14%, both SMILE cases) experienced a 1-line decrease in CDVA. The mean SE improved from − 6.42 ± 1.46 D preoperatively to -0.06 ± 0.04D; with procedure-specific improvements observed: SMILE eyes improved from − 6.00 ± 0.92 D to -0.01 ± 0.26 D, while FS-LASIK eyes improved from − 6.74 ± 1.72 D to -0.09 ± 0.49 D, postoperatively (all P < 0.001). Refractive predictability outcomes revealed 89.29% of eyes within ± 0.50 D (SMILE 100% vs. FS-LASIK 87.50%), 96.43% within ± 1.00 D (SMILE 100% vs. FS-LASIK 93.75%), and 96.00% with astigmatism ≤ 0.50 D (SMILE 100% vs. FS-LASIK 93.75%). During the follow-up, dry eye syndrome occurred in 4 of 14 patients (28.57%, 2 SMILE and 2 FS-LASIK cases), but there were no serious complications, and no healthcare staff contracted HIV.
conclusionsLaser lamellar corneal refractive surgery in HIV-positive patients demonstrated promising clinical outcomes. It was found to be safe for both healthcare professionals and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.